| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
7,090 |
5,318 |
$559K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,074 |
2,378 |
$343K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,453 |
1,326 |
$157K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,245 |
1,079 |
$124K |
| 87428 |
|
2,239 |
1,424 |
$51K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
446 |
415 |
$47K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
2,955 |
2,504 |
$46K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
3,754 |
2,974 |
$33K |
| 92587 |
|
1,803 |
1,649 |
$30K |
| 96160 |
|
7,838 |
5,143 |
$22K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,100 |
1,429 |
$22K |
| 90698 |
|
606 |
568 |
$14K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
115 |
111 |
$13K |
| 90686 |
|
599 |
557 |
$13K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
109 |
101 |
$12K |
| 90656 |
|
399 |
396 |
$9K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
82 |
81 |
$6K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
200 |
193 |
$6K |
| 96127 |
|
1,209 |
1,113 |
$6K |
| 90677 |
|
229 |
214 |
$5K |
| 90670 |
|
221 |
212 |
$5K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
79 |
78 |
$3K |
| 90680 |
|
115 |
112 |
$3K |
| 96161 |
|
1,005 |
779 |
$3K |
| 99177 |
|
484 |
443 |
$2K |
| 94760 |
|
2,356 |
1,651 |
$2K |
| 87807 |
|
193 |
131 |
$2K |
| 90633 |
|
55 |
53 |
$1K |
| 99173 |
|
384 |
357 |
$933.14 |
| 90744 |
|
24 |
24 |
$558.72 |
| 85018 |
|
229 |
214 |
$488.04 |
| 99051 |
|
41 |
40 |
$437.04 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
12 |
12 |
$151.08 |
| 36416 |
|
545 |
419 |
$63.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
12 |
12 |
$0.60 |